title: [Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders].
abstract: Autoimmune bullous skin disorders are characterized by a severe and potentially lethal course and may require aggressive long-term treatment with systemic corticosteroids and other immunosuppressive drugs, which can lead to serious adverse events. Recently, anti-CD20 antibody, Rituximab, was reported to be beneficial as an adjuvant therapy in these diseases. Herein, we present 2 case reports of patients suffering from resistant rare diseases from the aforementioned spectrum: linear IgA dermatosis and Pemphigoid gestationis. The patients were successfully treated with Rituximab (Mabthera). This is one of the first reports of this kind of treatment for these rare life-threatening diseases. These case reports emphasize the role of Rituximab as a crisis therapy in autoimmune blistering diseases.
authors: Department of Dermatology, Sheba Medical Center, Tel Hashomer, Ramat Gan. alinalozin@gmail.com
authors: Alina
authors: A
authors: Lozinski
authors: Sharon
authors: S
authors: Baum
authors: Lior
authors: L
authors: Sagi
authors: Alex
authors: A
authors: Volkov
authors: Henri
authors: H
authors: Trau
authors: Aviv
authors: A
authors: Barzilai
mesh_terms: D000328:Adult; D000743:Anemia, Hemolytic / Q000139:chemically induced; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D001706:Biopsy; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects; D004351:Drug Resistance; D005260:Female; D019085:Fluorescent Antibody Technique, Direct / Q000379:methods; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D062027:Linear IgA Bullous Dermatosis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D006559:Pemphigoid Gestationis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D011241:Prednisone / Q000008:administration & dosage; D011247:Pregnancy; D011537:Pruritus / Q000209:etiology; D035583:Rare Diseases / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D000069283:Rituximab; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007155:Immunologic Factors; D000069283:Rituximab; D003622:Dapsone; D011241:Prednisone